论文部分内容阅读
《新英格兰医学杂志》(New England Journal of Medicine)在2012年8月28日发表了一项关于血流储备分数(FFR)指导稳定性冠状动脉患者选择经皮冠状动脉介入治疗(PCI)还是药物治疗的一项注册研究(FAME2Trial)结果。这项前瞻性登记研究表明,在稳定型冠状动脉疾病和功能性显着狭窄的患者中,FFR指导的PCI加上最佳药物治疗的患者相比单独使用最佳药物治疗,减少紧急血运重建的需要。对于没有缺血表现的患者,单独使用药物治疗可得到有利的结果[NEnglJMed,2012,367(11):991-1001]。稳定型冠状动脉疾病患者的首选
On August 28, 2012, the New England Journal of Medicine published a report on FFR to guide the selection of patients with coronary artery disease who underwent percutaneous coronary intervention (PCI) or drugs Treatment of a registration study (FAME2Trial) results. This prospective registry study showed that in patients with stable coronary artery disease and significant stenosis, FFR-guided PCI plus optimal medication compared with best-in-class drug therapy alone, reduced emergency revascularization Need. For patients with no ischemic manifestations, favorable results can be obtained with drug treatment alone [NEnglJMed, 2012, 367 (11): 991-1001]. Preferred for patients with stable coronary artery disease